| Title: | Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank |
| Journal: | eLife |
| Published: | 5 Apr 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38578269/ |
| DOI: | https://doi.org/10.7554/elife.90132 |
| URL: | https://github.com/elifesciences/enhanced-preprints-data/raw/master/data/90132/v2/90132-v2.pdf |
Publication 9959
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background: Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated with various chronic diseases and mortality, but results are conflicting. Few studies examined the role of omega-6/omega-3 ratio in mortality.</p>
Methods: We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants who had complete information on circulating PUFAs, 6461 died during follow-up, including 2794 from cancer and 1668 from cardiovascular disease (CVD). Associations were estimated by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.</p>
Results: Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs increased (all Ptrend <0.05). Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15-38%) higher total mortality, 14% (95% CI, 0-31%) higher cancer mortality, and 31% (95% CI, 10-55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing stronger effects.</p>
Conclusions: Using a population-based cohort in UK Biobank, our study revealed a strong association between the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD mortality.</p>
Funding: Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
7 Authors
- Yuchen Zhang
- Yitang Sun
- Qi Yu
- Suhang Song
- J Thomas Brenna
- Ye Shen
- Kaixiong Ye
1 Application
| Application ID | Title |
|---|---|
| 48818 | Evaluate the causal effects of diet-modifiable biomarkers on clinical outcomes using Mendelian randomization |
Enabling scientific discoveries that improve human health